Representing Fearless andUndaunted Innovators.
The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Client Highlights
Wilson Sonsini Advises Energy Dome on Collaboration Agreement with Salt River Project
On June 15, 2026, Energy Dome, a leading provider of innovative capacity solutions for utilities and AI infrastructure, and Salt River Project (SRP), a not-for-profit public power utility serving the greater Phoenix metropolitan area, announced an agreement to add a 19-megawatt, 10-hour carbon dioxide-based battery system to the grid. The project is part of Google and SRP’s innovative collaboration to accelerate deployment of non-lithium-ion long-duration energy storage technologies that support reliability, affordability, and sustainability. Wilson Sonsini Goodrich & Rosati advised Energy Dome on the transaction.
Client Highlights
Firm Advises 4E Therapeutics on Acquisition by Eli Lilly
On June 16, 2026, 4E Therapeutics, an Austin-based neuroscience company developing next-generation treatments for chronic pain, announced that it has been acquired by Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised 4E Therapeutics on the transaction.
Client Highlights
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
Wilson Sonsini Advises Maneva on $27 Million Series A
On June 10, 2026, Maneva, the video-to-action AI company building the intelligence layer for modern manufacturing, announced $27 million in Series A funding, accelerating its mission to close the $18 trillion global manufacturing efficiency gap. The Series A round was led by U.S. Venture Partners (USVP), with participation from returning investors Bling Capital and Freestyle Capital, alongside a group of leading angel investors and funds. This fundraise brings Maneva’s total capital raised to $38.4 million. Wilson Sonsini Goodrich & Rosati advised Maneva on the transaction.
The proceeds from the Series A will position Maneva to accelerate on three fronts: deepening its core AI capabilities through continued development of its patent-pending VITA and ALIS agents, expanding its customer base into new geographies and industries, and rolling out its next generation of factory orchestration and AI knowledge agent features.
The Wilson Sonsini team that advised Maneva on the transaction included Rezwan Pavri, Lester Ang, Karin Hjorth, and Keili Prenton.
For more information, please see Maneva’s news release.
The proceeds from the Series A will position Maneva to accelerate on three fronts: deepening its core AI capabilities through continued development of its patent-pending VITA and ALIS agents, expanding its customer base into new geographies and industries, and rolling out its next generation of factory orchestration and AI knowledge agent features.
The Wilson Sonsini team that advised Maneva on the transaction included Rezwan Pavri, Lester Ang, Karin Hjorth, and Keili Prenton.
For more information, please see Maneva’s news release.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.